financetom
Business
financetom
/
Business
/
DeepSeek may face further regulatory actions, EU privacy watchdog says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DeepSeek may face further regulatory actions, EU privacy watchdog says
Feb 11, 2025 9:49 AM

BRUSSELS (Reuters) - DeepSeek may face more actions from national regulators in the future, Europe's privacy watchdog said on Tuesday, underscoring the bloc's concerns about the rising popularity of the cheap Chinese artificial intelligence startup.

National privacy regulators discussed DeepSeek at a monthly meeting on Tuesday, after Italy blocked the chatbot over lack of information on its use of personal data and as enforcers in France, the Netherlands, Belgium, Luxembourg and other countries questioned DeepSeek on its data collection practices.

"Several DPAs (data protection authorities) have already started actions vis-a-vis DeepSeek and there may be further actions in the future," a spokesperson for the European Data Protection Board (EDPB) said in an email after the meeting.

The concerns prompted the EDPB to broaden the scope of a taskforce created in April 2023 to foster cooperation and exchange information on enforcement related to AI.

The taskforce had originally focused only on Microsoft ( MSFT )-backed OpenAI's ChatGPT.

"In addition, the EDPB members underlined the need to coordinate DPAs' actions regarding urgent sensitive matters and for that purpose will set up a quick response team," the spokesperson said.

Europe has been in the forefront of protecting its citizens' privacy rights while its General Data Protection Regulation, which came into effect in 2018, is the toughest privacy law in the world.

(Reporting by Foo Yun Chee; Editing by Emelia Sithole-Matarise)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Stoneridge Names Troy Cooprider as Chief Technology Officer
Stoneridge Names Troy Cooprider as Chief Technology Officer
Mar 14, 2024
05:54 PM EDT, 03/14/2024 (MT Newswires) -- Stoneridge (SRI) said Thursday it appointed Troy Cooprider as its chief technology officer. Cooprider joined Stoneridge in 2020 as vice president of advanced engineering and engineering excellence. Most recently, he was Stoneridge's vice president of global technology, the company said. Price: 16.7, Change: -0.01, Percent Change: -0.05 ...
Antero Resources Insider Sold Shares Worth $736,357, According to a Recent SEC Filing
Antero Resources Insider Sold Shares Worth $736,357, According to a Recent SEC Filing
Mar 14, 2024
06:01 PM EDT, 03/14/2024 (MT Newswires) -- Sheri Pearce, Senior Vice President, Accounting and Chief Accounting Officer, on March 13, 2024, sold 28,009 shares in Antero Resources ( AR ) for $736,357. Following the Form 4 filing with the SEC, Pearce has control over a total of 106,698 shares of the company, with 106,698 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1433270/000110465924034602/xslF345X03/tm248897-1_4seq1.xml...
Ulta Beauty's annual profit forecast misses estimates as costs climb
Ulta Beauty's annual profit forecast misses estimates as costs climb
Mar 14, 2024
(Reuters) - Ulta Beauty ( ULTA ) on Thursday forecast full-year profit below Wall Street estimates after elevated supply chain costs and increased promotions hurt margins, sending its shares down 4.5% in extended trading. Despite the beauty retailer's efforts to boost sales through steep discounts, inflation-weary consumers cut back spending on discretionary items such as cosmetics and hair care products....
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial
Mar 14, 2024
06:00 PM EDT, 03/14/2024 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Thursday its sublingual film epinephrine experimental drug Anaphylm showed exposure levels comparable to autoinjectors and was quicker to reach maximum concentration in a phase 3 study. The two-part study focused on pharmacokinetics, the way a drug is absorbed, and pharmacodynamics, the way it affects the body, of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved